HOPE 3 trial: implications for practice

The HOPE-3 trial was presented earlier this month at the American College of Cardiology Scientific Sessions, and has been published in the New England Journal of Medicine with accompanying editorial this month.HOPE-3 consisted of three analyses looking at statin and blood pressure treatment in intermediate risk persons without cardiovascular disease (CVD). The study overall was performed as a 2by2 factorial. This trial included a total of 12,705 patients from a diverse range of backgrounds in 21 countries on six continents. The mean total cholesterol level was 5.21 mmol/l and mean LDL-cholesterol was 3.30 mmol/l.  The mean blood pressure was 138.1/91.9